Navigation Links
China Biologic Products Receives High-Technology Enterprise Certification to Qualify for Preferential Income Tax Rate
Date:2/11/2009

tement

This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the significance of the new preferential income tax rate and its effect on the Company's ability to increase its financial performance and become more competitive, and on the Company's overall production capacity, revenues and market share; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as ''believes,'' ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

  
'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
2. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
3. Syngenta Enters Into Research Collaboration With Anhui Academy, China
4. China Sky One Medical, Inc. CFO to Present at Roth Conference
5. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
6. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
7. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
8. China Biologic Products Enters into Short-Term Loan Agreement
9. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
10. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
11. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... , July 29, 2015  AsureQuality and ... molecular testing for applications in food and primary ... battery powered real-time PCR device, the Freedom4. ... right through to the supermarket shelf for producers, ... includes involvement in animal disease control and pest ...
(Date:7/29/2015)... Research and Markets ... the "Global Biosimilars Market, 2015 - 2025" ... Global Biosimilars Market, 2015 - 2025, report provides ... market. With the blockbuster biologics losing patent protection ... are being viewed as viable substitutes to the ...
(Date:7/29/2015)... July 29, 2015  AmnioChor Inc., an early stage ... very pleased to announce that the Musculoskeletal Transplant Foundation ... to invest in their seed round of development of ... storage capabilities. AmnioChor,s technology allows cryopreservation ... human stem cells living within those tissues. Amnion is ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2
... 11 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ( ... M. Gomez has joined Biomoda as a Senior,Research ... its,assay for the early detection of lung cancer., ... associate research scientist at,Lovelace Respiratory Research Institute in ...
... (Nasdaq: BCRX ) today announced Thomas J. ... interim Chief Medical Officer. Dr.,Simon brings more than ... his position at BioCryst., (Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO ... have Tom join BioCryst at this important time,",said ...
... Treatments have,commenced on the new Elekta Synergy(R) S ... a world-leading provider of intra- and,extracranial stereotactic radiosurgery., ... 30, 2007 with a colon,cancer treatment followed by ... patients treated with Elekta Synergy S are spine ...
Cached Biology Technology:Biomoda Hires Senior Scientist to Expand Research & Development Effort 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 2Elekta Announces Clinical Start-up of Elekta Synergy(R) S at UPMC 3
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
(Date:7/8/2015)... SPRINGS, Florida , July 8, 2015 ... constantly evolving as this summer,s must have products such as ... in demand as popularity for biometrics based devices continues to ... are NXT-ID, Inc. (NASDAQ: NXTD ), Google Inc. (NASDAQ: ... Inc. (NYSE: FIT ), GoPro, Inc. (NASDAQ: GPRO ...
(Date:7/2/2015)... 2015 Research and ... the "Natural Language Processing Market by Type ... Pattern & Image Recognition) - Worldwide Forecast to ... The key vendors occupying the market are 3M, ... Corporation, NetBase Solutions, SAS Institute Inc., Verint Systems ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... first oral, broad-spectrum angiogenesis inhibitor, specially formulated through nanotechnology, ... Children,s Hospital Boston. Findings were published online on June ... Because it is nontoxic and can be taken orally, ... preventive therapy for patients at high risk for cancer ...
... -- Clinician-scientists from NewYork-Presbyterian Hospital/Weill Cornell Medical Center are ... in the care of patients with traumatic brain injury ... be given nutritional supplementation through a gastric feeding tube ... their chances of survival by as much as four-fold. ...
... day, a staggering number of cells perform a feat that ... perfect replicas of each other. The process is called mitosis, ... hallmarks of cancer. Little is known about ... Fox Chase Cancer Center and Technion-Israel Institute of Technology in ...
Cached Biology News:New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 2New oral angiogenesis inhibitor offers potential nontoxic therapy for a wide range of cancers 3Following traumatic brain injury, balanced nutrition saves lives 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 2Death, division or cancer? Newly discovered checkpoint process holds the line in cell division 3
cystatin A (N-18)...
Human Cystatin A MAb (Clone 224705)...
...
... Ultra low freezers , Ultima ... critical material storage, Ultima II represents the ... in general purpose and blood bank configurations, ... IntrLogic microprocessor control system with built-in voltage ...
Biology Products: